Results 271 to 280 of about 5,239,733 (368)

Exosome Proteomics of SOD1D90A Mutation Suggest Early Disease Mechanisms, and FN1 as a Biomarker

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Amyotrophic lateral sclerosis (ALS) is a neuromuscular disease. Super oxide dismutase 1 (SOD1) gene mutations cause ALS, and the D90A mutation is associated with primarily upper motor neuron (UMN) loss. Objective Our goal is to reveal the early cellular events in ALS pathology and identify potential pharmacokinetic biomarkers, using well ...
Mukesh Gautam, Ali Laith, Aslihan Gunel, Melda Yilmaz, Nazli Basak, Halil Idrisoglu, P. Hande Ozdinler   +6 more
wiley   +1 more source

Explainable Artificial Intelligence: A Perspective on Drug Discovery. [PDF]

Pharmaceutics
Qadri YA, Shaikh S, Ahmad K, Choi I, Kim SW, Vasilakos AV.   +5 more
europepmc   +1 more source

Growth Differentiation Factor 15 Elevation in the Central Nervous System Is Associated With Failure to Thrive in Alexander Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Alexander disease (AxD) is a severe neurodegenerative disorder caused by gain‐of‐function mutations in the gene for GFAP, which lead to protein aggregation and a primary astrocytopathy. Symptoms vary, but failure to thrive (FTT) and frequent emesis are common and cause significant morbidity. Here we investigate GDF15, a member of the
Tracy L. Hagemann, Michelle M. Sonsalla, Cora Luzinski, Fernando Zacahua, David A. Harris, Dudley W. Lamming, Albee Messing   +6 more
wiley   +1 more source

Harnessing biological insights to accelerate drug discovery against ESKAPE pathogens. [PDF]

RSC Med Chem
Palmo T, Jamwal V, Kumari D, Singh K.
europepmc   +1 more source

Interleukin‐6 as a Key Biomarker in Facioscapulohumeral Dystrophy: Evidence From Longitudinal Analyses

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a progressive neuromuscular disorder with no approved treatments. Identifying reliable biomarkers is critical to monitor disease severity, activity, and progression. Interleukin‐6 (IL‐6) has been proposed as a candidate biomarker, but longitudinal validation is limited ...
Jonathan Pini, Emanuela Martinuzzi, Sandra Dhifallah, Abderhmane Slioui, Angela Puma, Luisa Villa, Michele Cavalli, Andra Ezaru, Jérémy Garcia, Manuela Gambella, Federico Torre, Luca Jacopo Pavan, Nicolas Glaichenhaus, Sabrina Sacconi   +13 more
wiley   +1 more source

Solvent Sustainability in Drug Discovery: Where Are We Now, and How Can We Improve? [PDF]

J Med Chem
Richardson P, Bryan MC, Diorazio L, Gallou F, Keily S, Martinez I, Plummer S, Reed AB, Sheppard R, Shields J, Wrigley G, Yeung C, Enríquez-García Á.   +12 more
europepmc   +1 more source

Accelerated Progression of Gait Impairment in Parkinson's Disease and REM Sleep Without Atonia

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective People with Parkinson's disease (PD) and rapid eye movement (REM) sleep without atonia (RSWA) often have more severe gait disturbances compared to PD without RSWA. The association between the presence and expression of RSWA and the rate of progression of gait impairment in PD is unknown.
Sommer L. Amundsen‐Huffmaster, Jae Woo Chung, Maria E. Linn‐Evans, Matthew N. Petrucci, Chiahao Lu, Destiny J. Weaver, Joshua De Kam, Scott E. Cooper, Paul J. Tuite, Aleksandar Videnovic, Michael J. Howell, Colum D. MacKinnon   +11 more
wiley   +1 more source

Advances in Drug Discovery for Cardiomyocyte Proliferation. [PDF]

Curr Treat Options Cardiovasc Med
Wintruba KL, Wolf MJ, van Berlo JH, Saucerman JJ.   +3 more
europepmc   +1 more source

Diffusion Tractography Biomarker for Epilepsy Severity in Children With Drug‐Resistant Epilepsy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To develop a novel deep‐learning model of clinical DWI tractography that can accurately predict the general assessment of epilepsy severity (GASE) in pediatric drug‐resistant epilepsy (DRE) and test if it can screen diverse neurocognitive impairments identified through neuropsychological assessments.
Jeong‐Won Jeong, Min‐Hee Lee, Hiroshi Uda, Yoon Ho Hwang, Michael Behen, Aimee Luat, Csaba Juhász, Eishi Asano   +7 more
wiley   +1 more source

Drug discovery and development for Parkinson's disease: are preclinical models good enough? [PDF]

Front Aging Neurosci
Reinares-Sebastián A, Esteban-García N, Takada M, Trigo-Damas I.   +3 more
europepmc   +1 more source